Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Prevention of Cognitive Decline in Alzheimer's Disease by Ingested Interferon Alpha
Authors not listed
National Center for Research Resources (NCRR)
Abstract
In this phase I-II parallel design, randomized, double-blind clinical trial we will determine if 3,000 or 30,000 units ingested hrIFN-a prevents deterioration of cognitive functioning in patients with dementia of Alzheimer's type (AD) and whether ingested hrIFN-a treatment decreases acute phase reactants and pro-inflammatory cytokine IL-6 in mild to moderate AD. We predict that the novel anti-inflammatory agent ingested human recombinant interferon alpha (hrIFN-a) will modulate inflammation and inhibit the natural history of AD progression. If you are eligible, you will receive Aricept for 5 weeks (donezepil) and thereafter in addition to Aricept either placebo (inactive substance) or interferon alpha at 3,000 or 30,000 units every day for 12 months.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-02 MST
Cite this
APA
Anonymous. (n.d.). Prevention of Cognitive Decline in Alzheimer's Disease by Ingested Interferon Alpha. <em>National Center for Research Resources (NCRR)</em>. https://clinicaltrials.gov/study/NCT00031018
Vancouver
Anonymous. Prevention of Cognitive Decline in Alzheimer's Disease by Ingested Interferon Alpha. National Center for Research Resources (NCRR).
BibTeX
@misc{anonndPreven,
title = {Prevention of Cognitive Decline in Alzheimer's Disease by Ingested Interferon Alpha},
author = {Anonymous},
journal = {National Center for Research Resources (NCRR)},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Sanofi 2003
Open access · US-GOV
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, 18-Month Study of the Efficacy of Xaliproden in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type
Samsung Medical Center 2014
Open access · US-GOV
A Pilot Study for the Improvement of Cognitive Function (ADAS-Cog 11) After Transcranial Direct Current Stimulation in Mild to Moderate Alzheimer's Disease
Florida Atlantic University 2007
Open access · US-GOV
Delaying the Progression of Driving Impairment in Individuals With Mild Alzheimer's Disease
Assiut University 2016
Open access · US-GOV
Therapeutic Role of Transcranial Direct Current Stimulation (tDCS) in Alzheimer Patients, Double Blind Placebo Controlled Clinical Trial
Aleksandra Stark 2017
Open access · US-GOV
A Phase IIa Proof of Concept, Randomized, Double-blind, Placebo-controlled Study of the Effects of L-serine on Early Stage Alzheimer's Disease Patients
US Department of Veterans Affairs 2007
Open access · US-GOV